Solventum Corporation
SOLV
Positions held
Your positionsSOLV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Solventum Corporation is well-positioned in the healthcare sector, focusing on innovative medical instruments that cater to a growing demand for advanced healthcare solutions.
- Revenue increased by 10% compared to the prior quarter, reaching $2.2 billion in Q2 2026.
- Gross margin improved to 58.2%, up from 54.6% in the previous quarter.
- The company faces challenges with a high debt-to-equity ratio of 110.31, indicating potential financial risk.
- Operating margin has fluctuated, with a decrease to 8.2% in Q2 2026 from 12.6% in 2024.
- The current recommendation is 'buy', but the overall score remains neutral at 12.00, suggesting caution.
Fundamentals
| Market cap | $14.71B | Enterprise value | $19.60B | Trailing P/E | 10.58 | Forward P/E | 11.95 |
| PEG | 1.22 | Price / book | 3.06 | Beta | 0.70 | Dividend yield | 0.00% |
| Revenue growth | 2.2% | Earnings growth | 3.9% | Gross margin | 54.8% | Operating margin | 9.8% |
| Profit margin | 17.3% | ROE | 34.0% | ROA | 2.7% | Debt / equity | 1.10 |
| Current ratio | 1.02 | Free cash flow | $489.00M | Analyst recommendation | buy | Mean target | $94.31 |
| 52w high | $94.16 | 52w low | $62.38 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $2.2B | $2.0B | $2.0B | $2.1B | $2.2B |
| Op margin | 8.2% | 3.9% | 4.7% | 8.2% | 9.9% |
| Net income | $92.0M | $13.0M | $63.0M | $1.3B | $90.0M |
| Gross margin | 58.2% | 54.6% | 51.4% | 54.2% | 54.4% |
| Gross profit | $1.3B | $1.1B | $1.0B | $1.1B | $1.2B |
| Operating income | $181M | $79.0M | $93.0M | $172M | $214M |
- Revenue +10% vs prior quarter ($2.2B vs $2.0B).
- Gross margin 58.2% (was 54.6% prior quarter).
- Operating margin expanded to 8.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $8.3B | $8.3B | $8.2B | $8.1B | — |
| Op margin | 7.6% | 12.6% | 20.0% | 20.8% | — |
| Net income | $1.6B | $479M | $1.3B | $1.3B | — |
| Gross margin | 53.5% | 55.6% | 57.3% | 57.7% | — |
| Gross profit | $4.5B | $4.6B | $4.7B | $4.7B | — |
| Operating income | $632M | $1.0B | $1.6B | $1.7B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?
2026-10-06 · Rothschild & Co Redburn Adjusts Price Target on Solventum to $75 From $70, Maintains Sell Rating
2026-10-02 · 3 Overrated Stocks We Approach with Caution
2026-09-29 · 2 Profitable Stocks for Long-Term Investors and 1 We Question
2026-09-25 · How Is Solventum's Stock Performance Compared to Other Healthcare Stocks
2026-09-17 · Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
2026-09-17 · What Solventum (SOLV)'s Earnings Beat and Surgical AI Push Means For Shareholders
2026-09-16 · Q2 Surgical Equipment & Consumables - Diversified Earnings: Solventum (NYSE:SOLV) Impresses
2026-09-09 · 3 S&P 500 Stocks with Open Questions
2026-09-04 · Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Price (daily)
Full chart · RSI · MACD · patterns